Cytokeratin (AE1/AE3) in addition to alpha-methylacyl coenzyme A racemase (P504S), 34-beta-E12, and p63 stains in evaluation of surgical specimens after hormonal therapy for prostatic adenocarcinoma.
Raspollini
Maria Rosaria
MR
D000230:Adenocarcinoma / Q000737:chemistry* / Q000175:diagnosis / Q000628:therapy; D000911:Antibodies, Monoclonal / Q000737:chemistry; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D003131:Combined Modality Therapy; D004268:DNA-Binding Proteins / Q000032:analysis*; D006801:Humans; D007150:Immunohistochemistry; D007633:Keratins / Q000032:analysis*; D008297:Male; D011471:Prostatic Neoplasms / Q000737:chemistry* / Q000175:diagnosis / Q000628:therapy; D019998:Racemases and Epimerases / Q000032:analysis*; D015203:Reproducibility of Results; D015534:Trans-Activators / Q000032:analysis*; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins / Q000032:analysis*
D000911:Antibodies, Monoclonal; D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; C121278:CK-34 beta E12; D004268:DNA-Binding Proteins; C115051:TP63 protein, human; D015534:Trans-Activators; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; D007633:Keratins; D019998:Racemases and Epimerases; C108352:alpha-methylacyl-CoA racemase